Overview

Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda

Status:
Unknown status

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

According to the national guidelines in Uganda and to the World Health Organization guidelines, HIV-infected patients should receive cotrimoxazole prophylaxis indefinitely. There are, however, concerns regarding the indefinite application of cotrimoxazole prophylaxis among patients immunologically stabilized on HAART (e.g. high pill burden, drug-drug interactions, toxicity and poor adherence because of treatment fatigue). To date no empirical evidence is available regarding the safety and optimal timing for the cessation of cotrimoxazole prophylaxis among HAART patients who successfully restored immunological competence. Research question: Does morbidity significantly differ between continuation (orthodox) and cessation (experimental) of cotrimoxazole prophylaxis among immuno-competent patients stable HAART in the resource-limited setting of Uganda?

Phase:

Phase 4

Details

Lead Sponsor:

MRC/UVRI and LSHTM Uganda Research Unit
MRC/UVRI Uganda Research Unit on Aids

Collaborator:

Medical Research Council

Treatments:

Trimethoprim, Sulfamethoxazole Drug Combination